Loading market dashboard
Arcturus Therapeutics Holdings Inc.
ARCTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings.
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the biotechnology company's stock after selling 115,500 shares
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.
Arcturus Therapeutics (NASDAQ: ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messenger RNA (mRNA) medicines before the pandemic and is now
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one
Arcturus Therapeutics (NASDAQ: ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three Phase 2 cohorts and is preparing to initiate a longer 12-week study designed to better evaluate lung function outcomes. CF program: 28-day cohorts
